Anticholinergics and prokinetics are mainstays of therapy for Irritable Bowel Syndrome (IBS)
patients despite their limited efficacy and troublesome side-effect profile. The clinical
limitations of these drugs are a result of their relative broad and nonspecific pharmacologic
interaction with various receptors. Recent advances in gut physiology have led to the
identification of various receptor targets that may play a pivotal role in the pathogenesis of
IBS. Medicinal chemists searching for safe and effective IBS therapies are now developing …